WuXi AppTec's leading position in CRO is solid, but it continues to be suppressed by the legislative risks of the U.S. "Biosecurity Act," with its valuation remaining in a historically low range for an extended period.
Hengrui Medicine has passed through the difficult period of its transformation into an innovative drug company in mainland China, with multiple pipeline products reaching key clinical milestones, and its GLP-1 layout is also accelerating.
RemeGen has clear competitiveness in the antibody-drug conjugate (ADC) field, and the overseas licensing progress of products like RC48 is a core catalyst.
Deshi is a promising newcomer in the gene and cell therapy sector on the Hong Kong stock market, early-stage but with high growth potential.
Hong Kong's biopharmaceutical sector has been suppressed by geopolitical and regulatory risks this year, but frequent M&A activities suggest that global pharmaceutical giants have started bargain hunting, indicating clear bottom valuation characteristics.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
